2-吡咯烷丙醇,1-甲基- | 14498-44-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 2-吡咯烷丙醇,1-甲基-
• 英文名称: 3-(1-methyl-2-pyrrolidyl)propan-1-ol
• 英文别名: N-Methyl-2-(3-hydroxy-propyl)-pyrrolidin；1-Methyl-2-<3-hydroxy-propyl>-pyrrolidin；1-Methyl-2-(3-hydroxy-propyl)-pyrrolidin；2-(3-Hydroxy-1-propyl)-1-methyl-pyrrolidin；N-Methyl-2-<3-hydroxy-propyl>-pyrrolidin；3-(1-methyl-pyrrolidin-2-yl)-propan-1-ol；1-(N-Methylpyrrolid-2-yl)-propan-3-ol；3-(N-Methylpyrrolid-2-yl)-propan-1-ol；2-Pyrrolidinepropanol, 1-methyl-；3-(1-methylpyrrolidin-2-yl)propan-1-ol
• CAS: 14498-44-3
• 化学式: C₈H₁₇NO
• 分子量: 143.229
• InChiKey: VJMMRHHALGZANP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-吡咯烷丙醇,1-甲基- 以77%的产率得到
  参考文献：
  名称：

  NORITSINA M. V.; KLOCHKOVA I. N.; BYKOVSKAYA T. S., XIMIYA GETEROTSIKL. SOEDIN. , 1976, HO 2, 186-190

  摘要：

  DOI：
• 作为产物：
  描述：

  (3-呋喃-2-丙基)-甲胺 在 nickel ruthenium 氢气 、 氢气 作用下， 生成 2-吡咯烷丙醇,1-甲基-
  参考文献：
  名称：

  Search for potential cholinesterase inhibitors among substituted pyrrolidines and piperazines

  摘要：

  DOI：

  10.1007/bf02974938

文献信息

• [EN] FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRAZOLE KINASE FUSIONNEE TRICYCLIQUE ET TETRACYCLIQUE
  申请人：ABBOTT LAB

  公开号：WO2004080973A1

  公开（公告）日：2004-09-23

  Compounds having the formula (I) (I), are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有化学式(I) (I)的化合物对抑制蛋白激酶很有用。还公开了制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。
• Therapy
  申请人：——

  公开号：US20030225111A1

  公开（公告）日：2003-12-04

  The invention concerns the use of a quinazoline derivative of Formula (I) wherein Q 1 includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q 3 —X 1 — wherein X 1 includes a direct bond and O and Q 3 includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R 2 and R 3 is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q 2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human. 1

  该发明涉及使用式（I）的喹唑啉衍生物，其中Q1包括一个喹唑啉环，可选地取代为卤、三氟甲基和氰等基团，或者具有式Q3-X1-的基团，其中X1包括直接键和O，Q3包括芳基、芳基-(1-6C)烷基、杂环基和杂环基-(1-6C)烷基；R2和R3中的每一个是氢或(1-6C)烷基；Z包括O、S和NH；Q2包括芳基和芳基-(1-3C)烷基或其药用可接受盐，在制备药物时用于在温血动物（如人类）中产生抗血管生成和/或降低血管通透性的效果。
• Fused tri and tetra-cyclic pyrazole kinase inhibitors
  申请人：——

  公开号：US20040259904A1

  公开（公告）日：2004-12-23

  Compounds having the formula (I) 1 are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  化合物具有公式（I）1，对于抑制蛋白激酶具有用途。还公开了制备该化合物的方法，含有该化合物的组合物以及使用该化合物的治疗方法。
• Amidobenzamide derivatives which are useful as cytokine inhibitors
  申请人：Brown S. Dearg

  公开号：US20050038081A1

  公开（公告）日：2005-02-17

  The invention concerns amide derivatives of the Formula (I) wherein R 3 is (1-6C)alkyl or halogeno; Q is aryl or heteroaryl which optionally bears 1, 2, 3 or 4 substituents such as hydroxy, halogeno, trifluoromethyl, cyano, (1-6C)alkyl, (1-6C)alkoxy, halogeno-(1-6C)alkyl, hydroxyl-(1-6C)alkyl, di-[(1-6C)akly]amino-(1-6C)alkyl, hydroxy-(2-6C)alkoxy, (1-6C)alkoxy-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, amino(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-(2-6C)alkylamino, aryl, aryl-(1-6C)alkoxy, heteroaryl, heteroaryl-(1-6C)alkoxy, heterocyclyl, heterocyclyl-(1-6C)alkyl, heterocyclyloxy and heterocyclyl-(1-6C)alkoxy; p is 0-2 and R 2 is a substituent such as hydroxy and halogeno; q is 0-4; and R 4 includes optionally substituted aryl, cycloalkyl, heteroaryl and heterocyclyl; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

  本发明涉及公式（I）的酰胺衍生物，其中R3是（1-6C）烷基或卤素基; Q是芳基或杂环芳基，其可选地带有1、2、3或4个取代基，例如羟基、卤素基、三氟甲基、氰基、（1-6C）烷基、（1-6C）烷氧基、卤代（1-6C）烷基、羟基（1-6C）烷基、二-[(1-6C)烷基]氨基（1-6C）烷基、羟基（2-6C）烷氧基、（1-6C）烷氧基（2-6C）烷氧基、二-[(1-6C)烷基]氨基（2-6C）烷氧基、氨基（2-6C）烷基氨基、N-(1-6C)烷基-(1-6C)烷基氨基-(2-6C)烷基氨基、芳基、芳基-(1-6C)烷氧基、杂环芳基、杂环芳基-(1-6C)烷氧基、杂环基、杂环基-(1-6C)烷基、杂环氧基和杂环基-(1-6C)烷氧基; p为0-2，R2是羟基和卤素基等取代基; q为0-4; R4包括可选的取代芳基、环烷基、杂环芳基和杂环基; 或其药学上可接受的盐或体内可水解的酯; 以及制备它们的方法、包含它们的制药组合物以及它们在治疗由细胞因子介导的疾病或医疗条件中的用途。
• SPIRO-CONDENSED INDOLE COMPOUNDS AS EHMT2 INHIBITORS
  申请人：Epizyme Inc

  公开号：EP4105203A1

  公开（公告）日：2022-12-21

  The present disclosure relates to substituted fused bi- or tri- heterocyclic compounds of formula (Va) to (Vf). The present disclosure also relates to pharmaceutical compositions containing these compounds. Said compounds are for use in methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2.

  本公开涉及式（Va）至（Vf）的取代融合二或三杂环化合物。本公开还涉及含有这些化合物的药物组合物。所述化合物用于通过抑制选自 EHMT1 和 EHMT2 的甲基转移酶来治疗疾病（例如镰状细胞贫血）的方法。